Novel Therapeutic Approaches and Targets for Treatment of Psoriasis

Author(s): Giulia Radi, Anna Campanati*, Federico Diotallevi, Tommaso Bianchelli, Annamaria Offidani

Journal Name: Current Pharmaceutical Biotechnology

Volume 22 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Psoriasis is a multifactorial immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2-3% of the worldwide population. Psoriasis involves skin, joints, or both, and it is associated with several comorbidities, including metabolic, rheumatological, cardiovascular, psychiatric complications, and other chronic inflammatory diseases, which are the expression of the complex underlying pathogenetic mechanism. An accurate characterization of the immune pathways involved in psoriasis led to recognize the new molecules, (IL)17 and 23, which become the new target of biologic therapy for moderate-to-severe plaque psoriasis.

Objective: The aim of this study is to collect data of literature about IL-17 and IL-23 inhibitors.

Methods: A descriptive review was conducted to identify the main data in the literature evaluating novel biologic treatments currently available: IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab).

Results: Dosing regimens, administration, efficacy, real-life efficacy and safety of IL-17 and IL-23 inhibitors are discussed in detail.

Conclusion: Currently approved novel biologic therapies for moderate to severe psoriasis revealed increasing effectiveness compared to previous biological therapy and a good safety profile.

Keywords: Psoriasis, ixekizumab, secukinumab, brodalumab, risankizumab, guselkumab, tidralkizumab.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 1
Year: 2021
Published on: 31 December, 2020
Page: [7 - 31]
Pages: 25
DOI: 10.2174/1389201021666200629150231
Price: $65

Article Metrics

PDF: 51